Richard Joseph Pietras

List of Publications by Year
in descending order

81 papers	6,937 citations	71102 41 h-index	79698 73 g-index
87 all docs	87 docs citations	87 times ranked	5067 citing authors

#	Article	IF	Citations
1	Investigation of Combination Treatment With an Aromatase Inhibitor Exemestane and Carboplatin-Based Therapy for Postmenopausal Women With Advanced NSCLC. JTO Clinical and Research Reports, 2021, 2, 100150.	1.1	2
2	Progesterone Receptor Signaling in the Breast Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2021, 1329, 443-474.	1.6	4
3	SUN-125 Phase Ib Study of Dual Therapy with an Aromatase Inhibitor Exemestane and Carboplatin-Based Therapy for Postmenopausal Women with Advanced Non-Small Cell Lung Cancer. Journal of the Endocrine Society, 2020, 4, .	0.2	0
4	Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy. Journal of Steroid Biochemistry and Molecular Biology, 2019, 193, 105415.	2.5	44
5	Squalamine blocks tumor-associated angiogenesis and growth of human breast cancer cells with or without HER-2/neu overexpression. Cancer Letters, 2019, 449, 66-75.	7.2	17
6	In Memorium: Clara M. Szego (1916â€“2017). Steroids, 2018, 135, 98-100.	1.8	0
7	Extranuclear signaling by sex steroid receptors and clinical implications in breast cancer. Molecular and Cellular Endocrinology, 2018, 466, 51-72.	3.2	38
8	Aromatase inhibitors combined with aspirin to prevent lung cancer in preclinical models. Translational Lung Cancer Research, 2018, 7, S373-S376.	2.8	2
9	Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer. Lung Cancer, 2018, 123, 91-98.	2.0	35
10	Estrogen receptor-beta is a potential target for triple negative breast cancer treatment. Oncotarget, 2018, 9, 33912-33930.	1.8	39
11	A83-01 inhibits TGF-Î²-induced upregulation of Wnt3 and epithelial to mesenchymal transition in HER2-overexpressing breast cancer cells. Breast Cancer Research and Treatment, 2017, 163, 449-460.	2.5	39
12	Receptors for Insulin-Like Growth Factor-2 and Androgens as Therapeutic Targets in Triple-Negative Breast Cancer. International Journal of Molecular Sciences, 2017, 18, 2305.	4.1	14
13	Incomplete Resolution of Deep Vein Thromboses during Rivaroxaban Therapy. Case Reports in Cardiology, 2017, 2017, 1-6.	0.2	5
14	CD24 Expression and differential resistance to chemotherapy in triple-negative breast cancer. Oncotarget, 2017, 8, 38294-38308.	1.8	35
15	Membrane Steroid Receptors â˜†. , 2017, , .		1
16	Possible failure of novel direct-acting oral anticoagulants in management of pulmonary embolism: a case report. Journal of Medical Case Reports, 2016, 10, 346.	0.8	12
17	Progesterone receptor (PR) polyproline domain (PPD) mediates inhibition of epidermal growth factor receptor (EGFR) signaling in non-small cell lung cancer cells. Cancer Letters, 2016, 374, 279-291.	7.2	22
18	Biologic Roles of Estrogen Receptor-Î²and Insulin-Like Growth Factor-2 in Triple-Negative Breast Cancer. BioMed Research International, 2015, 2015, 1-15.	1.9	35

#	Article	IF	Citations
19	Ribonucleotide Reductase Subunit M2 Predicts Survival in Subgroups of Patients with Non-Small Cell Lung Carcinoma: Effects of Gender and Smoking Status. PLoS ONE, 2015, 10, e0127600.	2.5	27
20	Estrogen Receptor-Î² and the Insulin-Like Growth Factor Axis as Potential Therapeutic Targets for Triple-Negative Breast Cancer. Critical Reviews in Oncogenesis, 2015, 20, 373-390.	0.4	6
21	Antiestrogen Fulvestrant Enhances the Antiproliferative Effects of Epidermal Growth Factor Receptor Inhibitors in Human Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2013, 8, 270-278.	1.1	59
22	The role of estrogen, progesterone and aromatase in human non-small-cell lung cancer. Lung Cancer Management, 2012, 1, 259-272.	1.5	27
23	Expression levels of estrogen receptor beta in conjunction with aromatase predict survival in non-small cell lung cancer. Lung Cancer, 2011, 74, 318-325.	2.0	62
24	Progesterone and estrogen receptor expression and activity in human non-small cell lung cancer. Steroids, 2011, 76, 910-20.	1.8	65
25	Targeting Aromatase and Estrogen Signaling in Human Nonâ€Small Cell Lung Cancer. Annals of the New York Academy of Sciences, 2009, 1155, 194-205.	3.8	106
26	Estrogen receptors outside the nucleus in breast cancer. Breast Cancer Research and Treatment, 2008, 108, 351-361.	2.5	150
27	Rational management of endocrine resistance in breast cancer. Cancer, 2008, 113, 2385-2397.	4.1	79
28	Aromatase Expression Predicts Survival in Women with Early-Stage Nonâ€“Small Cell Lung Cancer. Cancer Research, 2007, 67, 10484-10490.	0.9	126
29	Membrane-Associated Estrogen Receptor Signaling Pathways in Human Cancers. Clinical Cancer Research, 2007, 13, 4672-4676.	7.0	123
30	Estrogen receptor signaling pathways in human non-small cell lung cancer. Steroids, 2007, 72, 135-143.	1.8	198
31	The combination of green tea and tamoxifen is effective against breast cancer. Carcinogenesis, 2006, 27, 2424-2433.	2.8	94
32	Estrogen receptors in membrane lipid rafts and signal transduction in breast cancer. Molecular and Cellular Endocrinology, 2006, 246, 91-100.	3.2	92
33	Usefulness of 3â€²-[F-18]Fluoro-3â€²-deoxythymidine with Positron Emission Tomography in Predicting Breast Cancer Response to Therapy. Molecular Imaging and Biology, 2006, 8, 36-42.	2.6	208
34	Biologic Basis of Sequential and Combination Therapies for Hormoneâ€Responsive Breast Cancer. Oncologist, 2006, 11, 704-717.	3.7	43
35	Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistance. Breast Cancer Research and Treatment, 2005, 93, 11-18.	2.5	70
36	Antiangiogenic Steroids in Human Cancer Therapy. Evidence-based Complementary and Alternative Medicine, 2005, 2, 49-57.	1.2	48

#	Article	IF	Citations
37	Targeted Therapy: Wave of the Future. Journal of Clinical Oncology, 2005, 23, 1776-1781.	1.6	57
38	Rapid nitric oxide-mediated S-nitrosylation of estrogen receptor: Regulation of estrogen-dependent gene transcription. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 2632-2636.	7.1	93
39	Estrogen Receptors and Cell Signaling. Science, 2005, 310, 51-53.	12.6	47
40	Aromatase Inhibitors in Human Lung Cancer Therapy. Cancer Research, 2005, 65, 11287-11291.	0.9	161
41	New approaches to reverse resistance to hormonal therapy in human breast cancer. Drug Resistance Updates, 2005, 8, 219-233.	14.4	34
42	Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells. Steroids, 2005, 70, 372-381.	1.8	180
43	Plasma Membrane Receptors for Steroid Hormones in Cell Signaling and Nuclear Function. , 2005, , 67-84.		2
44	Rational Combinations of Trastuzumab With Chemotherapeutic Drugs Used in the Treatment of Breast Cancer. Journal of the National Cancer Institute, 2004, 96, 739-749.	6.3	488
45	Membrane receptors for steroid hormones: Signal transduction and physiological significance. Journal of Cellular Biochemistry, 2003, 88, 438-445.	2.6	69
46	Interactions Between Estrogen and Growth Factor Receptors in Human Breast Cancers and the Tumor-Associated Vasculature. Breast Journal, 2003, 9, 361-373.	1.0	73
47	Membrane Steroid Receptors. , 2003, , 657-671.		1
48	Membrane-Associated Estrogen Receptors and Breast Cancer. , 2003, , 1-9.		2
49	Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with or without HER-2 gene overexpression. Oncogene, 2002, 21, 2805-2814.	5.9	76
50	Steroid Hormone Receptors in Target Cell Membranes. Endocrine, 2001, 14, 417-428.	2.2	68
51	Epidermal Growth Factor Receptor and Tyrosine Phosphorylation of Estrogen Receptor. Endocrine, 2001, 16, 073-082.	2.2	62
52	Membrane-associated binding sites for estrogen contribute to growth regulation of human breast cancer cells. Oncogene, 2001, 20, 5420-5430.	5.9	158
53	Cell membrane estrogen receptors resurface. Nature Medicine, 1999, 5, 1330-1330.	30.7	26
54	Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene, 1999, 18, 2241-2251.	5.9	645

#	Article	IF	Citations
55	Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells. Oncogene, 1999, 18, 6050-6062.	5.9	131
56	Oncogene Activation and Breast Cancer Progression. , 1999, , 133-153.		1
57	Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene, 1998, 17, 2235-2249.	5.9	353
58	The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene, 1997, 15, 537-547.	5.9	317
59	Subcellular distribution of oestrogen receptors. Nature, 1985, 317, 88-88.	27.8	24
60	Lysosomal Functions in Cellular Activation: Propagation of the Actions of Hormones and Other Effectors. International Review of Cytology, 1984, 88, 1-302.	6.2	69
61	Specific internalization of estrogen and binding to nuclear matrix in isolated uterine cells. Biochemical and Biophysical Research Communications, 1984, 123, 84-91.	2.1	32
62	Immunologic inhibition of estrogen binding and action in preputial-gland cells and their subcellular fractions. The Journal of Steroid Biochemistry, 1981, 14, 679-691.	1.1	5
63	Sex pheromone production by preputial gland: the regulatory role of estrogen. Chemical Senses, 1981, 6, 391-408.	2.0	20
64	Membrane Recognition and Effector Sites in Steroid Hormone Action. , 1981, , 307-463.		56
65	Estrogen-Induced Growth of Uterine Cells. , 1981, , 649-674.		0
66	Partial purification and characterization of oestrogen receptors in subfractions of hepatocyte plasma membranes. Biochemical Journal, 1980, 191, 743-760.	3.7	145
67	Metabolic and proliferative responses to estrogen by hepatocytes selected for plasma membrane binding-sites specific for estradiol-17?. Journal of Cellular Physiology, 1979, 98, 145-159.	4.1	70
68	Estrogen receptors in uterine plasma membrane. The Journal of Steroid Biochemistry, 1979, 11, 1471-1483.	1.1	172
69	Elevated serum cathepsin B1-like activity in women with neoplastic disease. Gynecologic Oncology, 1979, 7, 1-17.	1.4	51
70	Specific binding sites for oestrogen at the outer surfaces of isolated endometrial cells. Nature, 1977, 265, 69-72.	27.8	663
71	Differential effects of vasopressin on the water, calcium and lysosomal enzyme contents of mitochondria-rich and lysosome-rich (granular) epithelial cells isolated from bullfrog urinary bladder. Molecular and Cellular Endocrinology, 1976, 4, 89-106.	3.2	22
72	Vasopressin-induced redistribution of binding sites for concanavalin A at the surface of epithelial cells from urinary bladder. Nature, 1976, 264, 774-776.	27.8	16

#	Article	IF	Citations
73	The membrane action of antidiuretic hormone (ADH) on toad urinary bladder. Journal of Membrane Biology, 1975, 22, 107-123.	2.1	51
74	Surface modifications evoked by antidiuretic hormone in isolated epithelial cells: Evidence from lectin probes. Journal of Supramolecular Structure, 1975, 3, 391-400.	2.3	5
75	Endometrial cell calcium and oestrogen action. Nature, 1975, 253, 357-359.	27.8	247
76	Influence of antidiuretic hormone on release of lysosomal hydrolase at mucosal surface of epithelial cells from urinary bladder. Nature, 1975, 257, 493-495.	27.8	29
77	Steroid Hormone-Responsive, Isolated Endometrial Cells. Endocrinology, 1975, 96, 946-954.	2.8	39
78	Surface Modifications Evoked by Estradiol and Diethylstilbestrol in Isolated Endometrial Cells: Evidence from Lectin Probes and Extracellular Release of Lysosomal Protease. Endocrinology, 1975, 97, 1445-1454.	2.8	40
79	Routes of nonelectrolyte permeation across epithelial membranes. Journal of Membrane Biology, 1974, 17, 293-312.	2.1	114
80	Electrically and osmotically induced changes in permeability and structure of toad urinary bladder. Biochimica Et Biophysica Acta - Biomembranes, 1974, 332, 286-297.	2.6	56
81	Non-electrolyte Probes of Membrane Structure in ADH-treated Toad Urinary Bladder. Nature, 1974, 247, 222-224.	27.8	37